Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medicines Co Announces Positive Results In Phase 3 Trial Of Cangrelor In Treatment Of Patients Undergoing PCI

Tuesday, 8 Jan 2013 11:03am EST 

Medicines Co announced results for its pivotal Phase 3 clinical trial of cangrelor, which is in development to prevent platelet activation and aggregation that leads to thrombosis in the acute care setting, including in patients undergoing percutaneous coronary intervention (PCI). Following the recommendation of the trial's Data Safety Monitoring Board (DSMB) in July 2012 to continue the protocol as planned, the CHAMPION PHOENIX trial completed enrollment in October 2012. After data lock, the data analysis revealed that the protocol defined primary composite efficacy endpoint of death, myocardial infarction, ischemia driven revascularization and stent thrombosis at 48 hours was met. Cangrelor demonstrated statistically improvement as compared to clopidogrel. Safety outcomes were similar to those observed in prior trials. The trial results are planned to be presented at a upcoming scientific meeting. 

Company Quote

0.28 +1.03%
26 Dec 2014